Projected Healthcare Resource Use and Budget Impact of Once-Daily Extended-Release vs Twice-Daily Immediate-Release Ruxolitinib in Myelofibrosis (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-204; Location: LEVEL 3, HALL B3; "Once-daily XR ruxolitinib was projected to be economically neutral to cost-saving vs twice-daily IR treatment over 3 years. These findings support simplified dosing as a potentially relevant strategy to reduce acute-care burden in long-term MF management. Previously presented at Academy of Managed Care Pharmacy 2026."
HEOR • Myelofibrosis • Oncology
|
|
Sumit Verma BPharm,MS 1; Jordan Fortunato PharmD 1; Yijia Sun MS 2; Precious Nchekwube BPharm,MPH 2; Jialu He 2; Samuel Wagner MPharm,PhD 2; Shreekant Parasuraman BPharm PhD 1
|